Visualitza per autor "Jurczak, Wojciech"
Ara mostrant els elements 1-3 d 3
-
Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation
Hodkinson, Brendan P.; Schaffer, Michael; Brody, Joshua D.; Carpio Segura, Cecilia Carmen; Ben-Yehuda, Dina; Jurczak, Wojciech (Elsevier, 2021-01) -
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
Duell, Johannes; Maddocks, Kami J.; González-Barca, Eva; Liberati, Anna Marina; de Vos, Sven; Abrisqueta Costa, Pablo; Jurczak, Wojciech (Ferrata Storti Foundation, 2021-09) -
Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study
Duell, Johannes; André, Marc; GAIDANO, Gianluca; GONZALEZ BARCA, EVA; Jurczak, Wojciech; Abrisqueta, Pau (Ferrata Storti Foundation, 2024-02)